KeraNetics

KeraNetics is a private, commercial-stage biotech company specializing in regenerative medicine through its proprietary keratin-based biomaterial platform. The company's flagship product, KeraStat® Cream, is FDA-cleared and commercially available for the management of radiation dermatitis, a severe skin condition affecting cancer patients undergoing radiotherapy. With a foundation rooted in research from the Wake Forest Institute for Regenerative Medicine and initial goals to treat battlefield injuries, KeraNetics has successfully translated its platform into a marketed product with additional development programs in wound care. The company has secured government contracts and established a pharmacy distribution network to support its commercial growth.

Proprietary platform for extracting and formulating human hair-derived keratin proteins into biomaterials that modulate wound healing and tissue regeneration.

In radiation dermatitis, KeraStat® competes against a range of topical products including over-the-counter moisturizers (e.g., Aquaphor, Miaderm), prescription steroid creams, and other barrier films. Its differentiation is its FDA clearance for this specific indication and its novel keratin-based mechanism. In the broader wound care market, it would compete with advanced products from large medtech firms like 3M, Smith & Nephew, and Mölnlycke.